GILEAD SCIENCES SL
- Country
- ๐ช๐ธSpain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"
- Conditions
- Interventions
- First Posted Date
- 2003-01-09
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1800
- Registration Number
- NCT00051285
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
- Conditions
- First Posted Date
- 2002-09-30
- Last Posted Date
- 2009-04-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00046319
- Locations
- ๐บ๐ธ
University of California San Diego Medical Center, San Diego, California, United States
๐บ๐ธLos Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
๐บ๐ธRush Presbyterian, Chicago, Illinois, United States
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
- Conditions
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00042393
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
- Conditions
- First Posted Date
- 2002-07-15
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00041691
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
๐บ๐ธWashington Hospital Center, Washington, District of Columbia, United States
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
- Conditions
- First Posted Date
- 2002-07-15
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 75
- Registration Number
- NCT00041639
- Locations
- ๐บ๐ธ
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
๐บ๐ธVirginia Mason Medical Center, Seattle, Washington, United States
๐ณ๐ฑAcademic Medical Center, Amsterdam, Netherlands
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
- First Posted Date
- 2002-07-15
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00041652
- Locations
- ๐บ๐ธ
Hoag Cancer Center, Newport Beach, California, United States
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
- Conditions
- First Posted Date
- 2002-07-03
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT00040599
- Locations
- ๐บ๐ธ
Washington Hospital Center, Washington, District of Columbia, United States
๐บ๐ธHoag Cancer Center, Newport Beach, California, United States
๐บ๐ธUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
- First Posted Date
- 2002-05-14
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00036634
- Locations
- ๐บ๐ธ
Rockefeller University Hospital, New York, New York, United States
๐บ๐ธProtocare Trials Chicago Center for Clinical Trials, Chicago, Illinois, United States
๐บ๐ธStanford Positive Care Program, Palo Alto, California, United States
A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00002116
- Locations
- ๐บ๐ธ
Mount Zion Med Ctr / UCSF, San Francisco, California, United States
๐บ๐ธLos Angeles County - USC Med Ctr, Los Angeles, California, United States
๐บ๐ธJohns Hopkins Hosp, Baltimore, Maryland, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- ๐บ๐ธ
Pacific Oaks Med Group, Beverly Hills, California, United States
๐บ๐ธUniv of Colorado / Health Science Ctr, Denver, Colorado, United States
๐บ๐ธAIDS Research Consortium of Atlanta, Atlanta, Georgia, United States